SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: tnsaf who wrote (3001)12/12/2006 3:52:29 AM
From: idos  Respond to of 3576
 
"What will it do to non-cancer stem cells?"

Cancer stem cells are distinct from regular stem cells. Cancer stem cells accumulate mutations that change gene expression and therefore can be targeted specifically by this drug.



To: tnsaf who wrote (3001)12/12/2006 12:01:45 PM
From: Savant  Read Replies (1) | Respond to of 3576
 
My understanding is that the primary action is upon telomerase, ("the data demonstrated that GRN163L inhibited telomerase activity"), which is seldom present in normal cells, and if present, is usually transient in nature. I've read nothing so far, that would indicate the telomerase inhibition is harmful to non-cancerous cells.

Let us know if you find something that would indicate otherwise.

Best,
S.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News